Immunogenicity of an inactivated adjuvanted whole-virion influenza a (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection

Microbiology and Immunology

Volumn 54, Issue 2, 2010, Pages 81-88

  Ikeno, Daisuke ^a   Kimachi, Kazuhiko ^a   Kino, Yoichiro ^a   Harada, Seiichi ^a   Yoshida, Kayo ^a   Tochihara, Shinji ^a   Itamura, Shigeyuki ^b   Odagiri, Takato ^b   Tashiro, Masato ^b   Okada, Kenji ^c   Miyazaki, Chiaki ^d   Ueda, Kohji ^e  

^a KAKETSUKEN   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c FUKUOKA NATIONAL HOSPITAL   (Japan)

^d Fukuoka West Rehabilitation Center for Children   (Japan)

^e Seinan Jo Gakuin University   (Japan)

Author keywords

Influenza; Intramuscular injection; Pandemic; Subcutaneous injection

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOLOGICAL ADJUVANT; INFLUENZA A VACCINE NIBRG 14; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; AXILLA TEMPERATURE; BLOOD SAMPLING; CHILL; CONTROLLED STUDY; DIARRHEA; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCUBATION TIME; INFLUENZA; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALAISE; MALE; NORMAL HUMAN; PAIN; SEROLOGY; SKIN INDURATION; VACCINATION; VIRION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; VIRION; YOUNG ADULT;

EID: 76649098488     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2009.00191.x     Document Type: Article

References (28)

1. WHO. (2009) Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. Accessed July 1, 2009, at: http://www.who.int/csr/ disease/avian influenza/country/ cases table 2009 07 01/en/index.html.
2. WHO. (2009) Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic Vaccines. Accessed July 18, 2009, at: http://www.who.int/csr/disease/avian influenza/guidelines/ 200902 H5VaccineVirusUpdate.pdf.
3. WHO. (2007) Tables on the Clinical trials of pandemic influenza prototype vaccines. WHO meeting Available at: http://www.who.int/vaccine.research/ diseases/influenza/ flu trials tables/en/index3.html.
4. Tashiro M. (2003) Safety and efficacy of an inactivated whole-virion influenza A (H5N1) vaccine. MHLW Res: 200201019A (Japanese language only).
5. Hehme N., Engelmann H., KuenzelW., Neumeier E., Saenger R. (2004) Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103: 163-71.
6. Hehme N., Engelmann H., KunzelW., Neumeier E., Sanger R. (2002) Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191: 203-8.
7. Ninomiya A., Imai M., Tashiro M., Odagiri T. (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25: 3554-60.
8. Cook I.F., Barr I., Hartel G., Pond D., Hampson A.W. (2006) Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 24: 2395-402.
9. American Academy of Pediatrics. (1997) RED BOOK, 24th Edition (ISBN: 0-910761-85-x). p14.
10. Stephenson I.,Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91-5.
11. European Medicine Agency. (1997) Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). Available at: http://www.emea.europa.eu/ pdfs/human/ bwp/021496en.pdf.
12. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., Gao Q., Zhang Z., Liu Y.,Wang Z., Yang M., Sun R., Li C., Lin S., Ji M., Liu Y.,Wang X.,Wood J., Feng Z.,Wang Y., YinW. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368: 991-7.
13. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T.,Wolff M. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-51.
14. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M.,Wood J., Hoschler K., Zambon M.C. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657-64.
15. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S., Low-Baselli A., Vartian N., Bobrovsky R., Pavlova B.G., Pollabauer E.M., Kistner O., Barrett P.N. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573-84.
16. Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., Qiu Y.Z., Liu Y., Lu M., Liu L.Y., Dong S.S., Gao Q., Zhang X.M.,Wang N., YinW.D., Dong X.P. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48: 1087-95.
17. Stephenson I., Das R.G.,Wood J.M., Katz J.M. (2007) Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25: 4056-63.
18. Tada Y. (2008) Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza Other Respi Viruses 2: 261-6.
19. Kistner O., Howard M.K., Spruth M.,WodalW., Bruhl P., Gerencer M., Crowe B.A., Savidis-Dacho H., Livey I., Reiter M., Mayerhofer I., Tauer C., Grillberger L., MundtW., Falkner F.G., Barrett P.N. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-36.
20. Ruben F.L., Jackson G.G. (1972) A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis 125: 656-64.
21. Fisch A., Cadilhac P., Vidor E., Prazuck T., Dublanchet A., Lafaix C. (1996) Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 14: 1132-6.
22. Carlsson R.M., Claesson B.A., Kayhty H., Selstam U., Iwarson S. (1999) Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine 18: 468-78.
23. Mark A., Carlsson R.M., Granstrom M. (1999) Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 17: 2067-72.
24. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., Howe B.J., Dubin G. (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351: 2286-94.
25. Shital Patel R.A., El-Sahly H., Cate T., KeitelW. (2007) A Randomized, Open-Label, Phase I Clinical Trial Comparing the Safety, Reactogenicity, and Immunogenicity of Immunization with Inactivated Influenza A/H5N1 Vaccine Administered by the Intradermal (ID) or the Intramuscular (IM) Route Among Healthy Adults. Available at: http://www.who.int/vaccine research/diseases/ influenza/160207 keitel.pdf.
26. Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., Hoschler K., Bennet J., Ryan D., Papanaoum K., Basser R.L., Zambon M.C. (2008) Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26: 4160-7.
27. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., Devaster J.M., Leroux-Roels G. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-9.
28. Nicholson K.G., Colegate A.E., Podda A., Stephenson I.,Wood J., Ypma E., Zambon M.C. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-43.